Five-year treatment of chronic venous insufficiency with O-(β-hydroxyethyl)-rutosides: Safety aspects

International Journal of Angiology

Volumn 17, Issue 3, 2008, Pages 143-148

  Stuard, S ^a   Cesarone, Maria Rosaria ^b   Belcaro, Gianni ^b   Dugall, Mark ^b   Ledda, Andrea ^b   Cacchio, Marisa ^b   Ricci, Andrea ^b   Ippolito, Edmondo ^c   Renzo, Andrea Di ^b   Grossi, Maria Giovanna ^b  

^a Unitá Operative Dialisi Diaferesi   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Edema; Elastic compression; HR; Microangiopathy; O ( hydroxyethyl) rutosides; Safety; Tolerability; Ulcerations; Varicose veins; Veins; Venous; Venous disease

Indexed keywords

EID: 72849130643     PISSN: 10611711     EISSN: 16155939     Source Type: Journal    
DOI: 10.1055/s-0031-1278299     Document Type: Article

References (57)

1. Beckers C, Zijilstra JA. New aspects of the pathogenesis of CVI and the site of action of Venoruton®. Phlebol Dig 2001;14:8-11.
2. Belcaro G, Rulo A, Candiani C. Evaluation of the microcirculatory effects of Venoruton® in patients with chronic venous hypertension with laser Doppler flowmetry, transcutaneous PO2 and PCO2 measurements, leg volumetry and ambulatory venous pressure measurements. Phlebology 1989;4:23-26.
3. Cesarone MR, Ricci A, Belcaro G, et al. Acute effect of hydroxyethylrutosides on capillary filtration in normal volunteers, patients with venous hypertension and in patients with diabetic microangiopathy (a dose-comparison study). Vasa 1992;21:76-9.
4. Belcaro G, Errichi BM. Evaluation of capillary permeability in patients with venous hypertension treated with Venoruton® by the vacuum suction chamber (VSC) device. Phlebologie 1988;41:847-9.
5. Incandela L, Belcaro G, Renton S, et al. HR (Paroven, Venoruton®; O-(β-hydroxyethyl)-rutosides) in venous hypertensive microangiopathy: A prospective, placebocontrolled, randomized trial. J Cardiovasc Pharmacol Therap 2002;7(Suppl I):S7-10.
6. Incandela L, Cesarone MR, Belcaro G, Dugall M, Acerbi G. Treatment of diabetic microangiopathy and edema with HR (Paroven, Venoruton®; O-(β-hydroxyethyl)-rutosides): A prospective, placebo-controlled, randomized study. J Cardiovasc Pharmacol Therap 2002;7(Suppl I):S11-3.
7. Cesarone MR, Belcaro G, Geroulakos G, et al. Flight microangiopathy in medium-to-long-distance flights: Prevention of edema and microcirculation alterations with HR (Paroven, Venoruton®; O-(β-hydroxyethyl)-rutosides) . J Cardiovasc Pharmacol Therap 2002:7(Suppl I):S17-9.
8. Cesarone MR, Incandela L, De Sanctis MT, Belcaro G, Griffin M, Ippolito E. Treatment of edema and increased capillary filtration in venous hypertension with HR (Paroven, Venoruton®; O-(β- hydroxyethyl)-rutosides): A clinical, prospective, placebo-controlled, randomized, dose-ranging trial. J Cardiovasc Pharmacol Therap 2002;7(Suppl I):S21-5.
9. Cesarone MR, Incandela L, De Sanctis MT, Belcaro G, Dugall M, Acerbi G. Variations in plasma free-radicals in patients with venous hypertension with HR (Paroven, Venoruton®; O-(β-hydroxyethyl)-rutosides): A clinical, prospective, placebocontrolled, randomized trial. J Cardiovasc Pharmacol Therap 2002;7(Suppl I):S25-8. (Pubitemid 34408832)
10. Belcaro G, Nicolaides AN, Stansby G, eds. The Venous Clinic. London: Imperial College Press, 1999.
11. De Sanctis MT, Cesarone MR, Incandela L, Belcaro G, Acerbi G. Methods of evaluation and quantification of microangiopathy in high perfusion microangiopathy (Chronic venous insufficiency and diabetic microangiopathy). J Cardiovasc Pharmacol Therap 2002;7(Suppl I):S3-5.
12. Belcaro G, Nicolaides AN, eds. Noninvasive Investigations in Vascular Disease. London: Imperial College Press, 2001.
13. Almond NE, et al. A laser Doppler blood flowmeter used to detect thermal entrainment in normal persons and patients with Raynaud's phenomenon. In: Spence VA, Sheldon CD, eds. Practical Aspects of Skin Blood Flow Measurement. London: Biological Engineering Society, 1985.
14. Anning ST. The cause and treatment of leg ulcers. Lancet 1952;2:789-94.
15. Anning ST. Leg ulcers. Their causes and treatment. London: J & A Churchill Ltd, 1954.
16. Anning ST. The historical aspect. In: Dodd H, Cockett FB, eds. The Pathology and Surgery of the Veins of the Lower Limb. Edinburgh: Churchill-Livingstone, 1976.
17. Belcaro G. The role of transcutaneous PCO2 measurements in association with laser Doppler flowmetry in venous hypertension. Phlebology 1988;3:189-93.
18. Belcaro G, Grigg M, Rulo A, Nicolaides AN. Blood flow in the perimalleolar skin in relation to posture in patients with venous hypertension. Ann Vasc Surg 1989;1:5-8.
19. Belcaro G, Christopoulos D, Nicolaides AN. Skin flow and swelling in postphlebitic limbs. Vasa 1989;18:136-8.
20. Belcaro G, Nicolaides AN, Volteas N, Leon M. Skin flow, the venoarteriolar response and capillary filtration in diabetics. A three-year follow-up study. Angiology 1992;43:490-4.
21. Belcaro G, Bollinger A, Hoffman U, Nicolaides AN, eds. Laser Doppler Flowmetry. London: Med-Orion, 1994.
22. Bergan JJ, Schmid-Schonbein GW, Takase S. Therapeutic approach to chronic venous insufficiency and its complications: Place of Daflon 500 mg. Angiology 2001;52(Suppl 1):S43-5.
23. Bollinger A, Jäger K, Geser A, Sgier F, Seglias J. Transcapillary and interstitial diffusion of Na-fluorescein in chronic venous insufficiency with white atrophy. Int J Microcirc Clin Exp 1982;1:5-17.
24. Fagrell B. Local microcirculation in chronic venous incompetence and leg ulcers. Vasc Surg 1979;13:217-9.
25. Fagrell B. Microcirculatory disturbances - the final cause for venous leg ulcers? Vasa 1982;11:101-3. (Pubitemid 12030268)
26. Fagrell B. Problems using laser Doppler flowmetry on the skin in clinical practice. In: Belcaro G, Hoffman U, Nicolaides AN, Bollinger A, eds. Laser Doppler. London: Med Orion, 1994:49-53.
27. Franzeck U, Bollinger A, Huch R, Huch A. Transcutaneous oxygen tension and capillary morphologic characteristics and density in patients with chronic venous incompetence. Circulation 1984;70:806-9.
28. Henriksen O. Local reflex in microcirculation in human subcutaneous tissue. Acta Physiol Scand 1976;97:447-56.
29. Rayman G, Hassan A, Tooke JE. Blood flow in the skin of the foot related to posture in patients with diabetes mellitus. Br Med J 1986;292:87-91.
30. Thulesius O. Capillary filtration under normal and pathological conditions. Angiologia 1973;10:198-201.
31. Grossi MG, Belcaro G, Cesarone MR. Iontophoresis, a model of venous hypertension and microangiopathy with histamine injection. 2008. (In press)
32. Grossi MG, Belcaro G, Cesarone MR. Iontophoresis, a model of venous hypertension and microangiopathy with reactive hyperemia. Angiology 2008. (In press)
33. Poynard T, Valterio C. Meta-analysis of hydroxyethylrutosides in the treatment of chronic venous insufficiency. Vasa 1994;23:244-60.
34. Ekestrom S, Welti R. The affinity of hydroxyethyl-rutosides for the venous wall and its efficacy in preventing early occlusion of aortocoronary vein bypass grafts. Phlebology 1990;5(Suppl 1):41-8.
35. Nees S, Juchem G, Fink R, et al. Influence of polymorphonuclear leukocytes and platelets on the barrier function of cultured venular endothelial cells. In: Messmer K, Kubler W, eds. Proceedings of the 6th World Congress for Microcirculation, Munich, Germany. Bologna: Monduzzi Editore, 1996:401-4.
36. Roland IH, Bougelet C, Ninane N, Arnaud T, Michiels C, Remacle J. Effect of hydroxyethylrutosides on hypoxial-induced neutrophil adherence to umbilical vein endothelium. Cardiovasc Drugs Ther 1998;12:375-81. (Pubitemid 28479171)
37. Liu F, Xu Y, Rui L, Gao S, Dong H, Guo Q. Liquid chromatography/tandem mass spectrometry assay for the quantification of troxerutin in human plasma. Rapid Commun Mass Spectrom 2006;20:3522-6. (Pubitemid 44871307)
38. Yang X, Wang F, Hu S. The electrochemical oxidation of troxerutin and its sensitive determination in pharmaceutical dosage forms at PVP modified carbon paste electrode. Colloids Surf B Biointerfaces 2006;52:8-13. (Pubitemid 44301871)
39. Cesarone MR, Belcaro G, Pellegrini L, et al. Circulating endothelial cells in venous blood as a marker of endothelial damage in chronic venous insufficiency: Improvement with Venoruton®. J Cardiovasc Pharmacol Ther 2006;11:93-8.
40. Cesarone MR, Belcaro G, Pellegrini L, et al. Venoruton® vs Daflon: Evaluation of effects on quality of life in chronic venous insufficiency. Angiology 2006;57:131-8. (Pubitemid 44438564)
41. Cesarone MR, Belcaro G, Pellegrini L, et al. HR, O-(β-hydroxyethyl)- rutosides; (Venoruton®): Rapid relief of signs/symptoms in chronic venous insufficiency and microangiopathy: A prospective, controlled study. Angiology 2005;56:165-72. (Pubitemid 40404471)
42. Gutierrez RM, Solis RV, Baez EG, Martinez FM. Effect on c apillary permeability in rabbits of iridoids from Buddleia scordioides. Phytother Res 2006;20:542-5. (Pubitemid 44065134)
43. Furfaro AL, Menini S, Patriarca S, et al. HNE-dependent molecular damage in diabetic nephropathy and its possible prevention by N-acetyl-cysteine and oxerutin. Biofactors 2005;24:291-8. (Pubitemid 41750553)
44. Maurya DK, Balakrishnan S, Salvi VP, Nair CK. Protection of cellular DNA from gamma-radiation-induced damages and enhancement in DNA repair by troxerutin. Mol Cell Biochem 2005;280:57-68. (Pubitemid 41829800)
45. Chung HK, Choi SM, Ahn BO, Kwak HH, Kim JH, Kim WB. Efficacy of troxerutin on streptozotocin-induced rat model in the early stage of diabetic retinopathy. Arzneimittelforschung 2005;55:573-80. (Pubitemid 41546102)
46. Cesarone MR, Belcaro G, Ricci A, et al. Prevention of edema and flight microangiopathy with Venoruton® (HR), (O-[β-hydroxyethyl]-rutosides) in patients with varicose veins. Angiology 2005;56:289-93. (Pubitemid 40656431)
47. Adam BS, Pentz R, Siegers CP, Strubelt O, Tegtmeier M. Troxerutin protects the isolated perfused rat liver from a possible lipid peroxidation by coumarin. Phytomedicine 2005;12:52-61. (Pubitemid 40174329)
48. Kulisic T, Krisko A, Dragovic-Uzelac V, Milos M, Pifat G. The effects of essential oils and aqueous tea infusions of oregano (Origanum vulgare L. spp. hirtum), thyme (Thymus vulgaris L.) and wild thyme (Thymus serpyllum L.) on the copper-induced oxidation of human low-density lipoproteins. Int J Food Sci Nutr 2007;58:87-93. (Pubitemid 47161432)
49. Hsu IP, Jou HJ, Huang CW, Wang TA, Wu WH. The effects of soygerm extracts on blood lipoproteins, antioxidative capacity and urinary estrogen metabolites in postmenopausal women on hormone therapy. Int J Gynaecol Obstet 2007;98:29-33. (Pubitemid 46898391)
50. Botelho FV, Alvarez-Leite JI, Lemos VS, et al. Physicochemical study of floranol, its copper (II) and iron (III) complexes, and their inhibitory effect on LDL oxidation. J Inorg Biochem 2007;101:935-43. (Pubitemid 46770854)
51. Cirillo M, De Santo NG. La microalbuminuria in adulti non diabetici. G Ital Nefrol 2002;19:273-7.
52. Murtaugh MA, Jacobs D, Yu X, Gross MD, Steffes M. Correlates of urinary albumin excretion in young blacks and whites. The Coronary Artery Risk Development in Young Adults Study. Am J Epidemiol 2003;158:676-86. (Pubitemid 37175516)
53. Teixeira SR, Tappenden KA, Carson LA, et al. Isolated soy protein consumption reduces urinary albumin excretion and improves the serum lipid profile in men with type 2 diabetes mellitus and nephropathy. J Nutr 2004;134:1874-80. (Pubitemid 39031310)
54. Cesarone MR, Incandela L, DeSanctis MT, Belcaro G, Griffin M, Ippolito E. Treatment of edema and increased capillary filtration in venous hypertension with HR (Paroven, Venoruton®; O-(β-hydroxyethyl)-rutosides): A clinical, prospective, placebocontrolled, randomized, dose-ranging trial. J Cardiovasc Pharmacol Ther 2002;7(Suppl 1):S21-4. (Pubitemid 34408831)
55. Belcaro G, Cesarone MR, Ledda A, et al. HR (β-hydroxyethyl)- rutosides: Associated systemic and local treatment in chronic venous disease and microangiopathy. An independent, prospective, comparative study. Angiology 2008. (In press)
56. Milde J, Elstner EF, Grassmann J. Synergistic effects of phenolics and carotenoids on human low-density lipoprotein oxidation. Mol Nutr Food Res 2007;51:956-61. (Pubitemid 47292269)
57. Belcaro G, Cesarone MR, Ledda A, et al. 5-Year control and treatment of edema and increased capillary filtration in venous hypertension and diabetic microangiopathy using O-(β-hydroxyethyl)-rutosides: A prospective comparative clinical registry. Angiology 2008;59(Suppl 1):14S-20S. (Pubitemid 351253078)